Published in Clin Cancer Res on March 23, 2010
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid Cancer | NCT02363647
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer (2010) 5.82
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature (2012) 2.33
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell (2011) 2.28
Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest (2013) 2.06
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
MEK and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.90
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83
Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res (2010) 1.77
Melanoma: new insights and new therapies. J Invest Dermatol (2012) 1.54
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. J Natl Cancer Inst (2011) 1.50
Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell Int (2016) 1.42
MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Br J Cancer (2016) 1.39
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. Cell (2017) 1.38
High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood (2011) 1.28
Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. Oncotarget (2013) 1.27
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discov (2015) 1.17
Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology (2012) 1.09
The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer (2010) 1.05
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer (2012) 1.03
PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots? Trends Cardiovasc Med (2011) 1.00
MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J (2013) 0.99
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish. Dis Model Mech (2012) 0.96
Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov (2014) 0.95
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemother Pharmacol (2011) 0.94
A novel loss-of-function mutation in Npr2 clarifies primary role in female reproduction and reveals a potential therapy for acromesomelic dysplasia, Maroteaux type. Hum Mol Genet (2012) 0.92
Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy. Curr Med Chem (2011) 0.92
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1. Pediatr Blood Cancer (2015) 0.91
The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood (2011) 0.91
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res (2015) 0.91
Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). ACS Med Chem Lett (2012) 0.89
MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther (2011) 0.89
Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol (2015) 0.86
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. PLoS One (2014) 0.85
Chemical genetics of rapamycin-insensitive TORC2 in S. cerevisiae. Cell Rep (2013) 0.83
Targeting RAS-mutant cancers: is ERK the key? Trends Cancer (2015) 0.82
Targeting MEK for the treatment of non-small-cell lung cancer. J Thorac Oncol (2012) 0.82
Mutation of the retinoblastoma tumor suppressor gene sensitizes cancers to mitotic inhibitor induced cell death. Am J Cancer Res (2014) 0.82
Remote loading of preencapsulated drugs into stealth liposomes. Proc Natl Acad Sci U S A (2014) 0.82
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice. PLoS One (2013) 0.81
Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol (2012) 0.79
Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation. Am J Pathol (2013) 0.78
Infrequent methylation of the DUSP6 phosphatase in endometrial cancer. Gynecol Oncol (2010) 0.77
Genomic alterations in pancreatic cancer and their relevance to therapy. World J Gastrointest Oncol (2015) 0.77
Disentangling the Complexity of HGF Signaling by Combining Qualitative and Quantitative Modeling. PLoS Comput Biol (2015) 0.77
Integrating Domain Specific Knowledge and Network Analysis to Predict Drug Sensitivity of Cancer Cell Lines. PLoS One (2016) 0.77
ETS1 inactivation causes innate drug resistance to EGFR inhibitors. Mol Cell Oncol (2015) 0.76
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. Oncologist (2016) 0.76
Biliverdin reductase: a target for cancer therapy? Front Pharmacol (2015) 0.75
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. Invest New Drugs (2016) 0.75
Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors. Elife (2016) 0.75
Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma. Oncotarget (2015) 0.75
Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts. Int J Oncol (2015) 0.75
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. Cancer Chemother Pharmacol (2016) 0.75
Evolving pharmacotherapies for the treatment of metastatic melanoma. Clin Med Insights Oncol (2013) 0.75
Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett (2017) 0.75
Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene (2017) 0.75
Loss of ERK1/2 in the retinal pigment epithelium leads to RPE65 decrease and retinal degeneration. Mol Cell Biol (2017) 0.75
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med (2014) 10.91
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res (2006) 5.69
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol (2005) 5.23
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res (2007) 3.74
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res (2010) 3.68
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res (2011) 3.56
Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res (2006) 3.55
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol (2005) 3.48
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol (2011) 3.44
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.40
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature (2011) 3.18
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov (2012) 3.04
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol (2011) 3.00
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol (2005) 2.86
Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol (2015) 2.80
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol (2012) 2.76
Retracted Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol (2009) 2.75
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res (2011) 2.74
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol (2008) 2.65
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.59
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol (2011) 2.58
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol (2006) 2.58
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol (2004) 2.55
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol (2009) 2.54
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol (2012) 2.52
The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer (2010) 2.43
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Improvement in oncology practice performance through voluntary participation in the Quality Oncology Practice Initiative. J Clin Oncol (2008) 2.39
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood (2012) 2.37
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet (2008) 2.36
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res (2008) 2.34
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol (2003) 2.32
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 2.31
Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol (2012) 2.21
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 2.19
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park) (2010) 2.10
D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res (2013) 2.05
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res (2011) 2.03
Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol (2012) 2.02
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res (2012) 2.02
EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn (2008) 1.99
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol (2010) 1.94
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol (2007) 1.91
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol (2004) 1.90
Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol (2004) 1.89
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol (2008) 1.79
Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol (2009) 1.79
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol (2011) 1.76
Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res (2011) 1.76
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol (2013) 1.73
Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer (2005) 1.73
Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol (2013) 1.71
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer (2005) 1.69
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer (2004) 1.68
Measuring supportive care in medical oncology practice: lessons learned from the quality oncology practice initiative. J Clin Oncol (2008) 1.67
Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol (2012) 1.66
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res (2013) 1.66
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol (2007) 1.66
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist (2014) 1.61
Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol (2010) 1.61
The prevalence of weight concerns in a smoking abstinence clinical trial. Addict Behav (2005) 1.60
Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res (2007) 1.60
Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther (2014) 1.57
Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med (2011) 1.56
Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res (2012) 1.56